1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Vestibular Diseases - Pipeline Review, H2 2014

Vestibular Diseases - Pipeline Review, H2 2014

  • November 2014
  • -
  • Global Markets Direct
  • -
  • 26 pages

Vestibular Diseases - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Vestibular Diseases - Pipeline Review, H2 2014’, provides an overview of the Vestibular Diseases’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Vestibular Diseases, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vestibular Diseases and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vestibular Diseases
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Vestibular Diseases and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Vestibular Diseases products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Vestibular Diseases pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Vestibular Diseases
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Vestibular Diseases pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Vestibular Diseases - Pipeline Review, H2 2014
Table of Contents

Introduction 4
Global Markets Direct Report Coverage 4
Vestibular Diseases Overview 5
Therapeutics Development 6
Pipeline Products for Vestibular Diseases - Overview 6
Pipeline Products for Vestibular Diseases - Comparative Analysis 7
Vestibular Diseases - Therapeutics under Development by Companies 8
Vestibular Diseases - Pipeline Products Glance 9
Early Stage Products 9
Vestibular Diseases - Products under Development by Companies 10
Vestibular Diseases - Companies Involved in Therapeutics Development 11
Griffin Discoveries BV 11
Quark Pharmaceuticals, Inc. 12
Sensorion S.A.S. 13
Vestibular Diseases - Therapeutics Assessment 14
Assessment by Monotherapy Products 14
Assessment by Target 15
Assessment by Mechanism of Action 16
Assessment by Molecule Type 17
Drug Profiles 19
SENS-100 - Drug Profile 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
SENS-200 - Drug Profile 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
SENS-300 - Drug Profile 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
siRNA for CNS Disorders - Drug Profile 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
Small Molecules to Antagonize Histamine H4 Receptor for Vestibular Disorders - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Vestibular Diseases - Dormant Projects 24
Appendix 25
Methodology 25
Coverage 25
Secondary Research 25
Primary Research 25
Expert Panel Validation 25
Contact Us 26
Disclaimer 26

List of Tables

Number of Products under Development for Vestibular Diseases, H2 2014 6
Number of Products under Development for Vestibular Diseases - Comparative Analysis, H2 2014 7
Number of Products under Development by Companies, H2 2014 8
Comparative Analysis by Early Stage Development, H2 2014 9
Products under Development by Companies, H2 2014 10
Vestibular Diseases - Pipeline by Griffin Discoveries BV, H2 2014 11
Vestibular Diseases - Pipeline by Quark Pharmaceuticals, Inc., H2 2014 12
Vestibular Diseases - Pipeline by Sensorion S.A.S., H2 2014 13
Assessment by Monotherapy Products, H2 2014 14
Number of Products by Stage and Target, H2 2014 15
Number of Products by Stage and Mechanism of Action, H2 2014 16
Number of Products by Stage and Molecule Type, H2 2014 18
Vestibular Diseases - Dormant Projects, H2 2014 24

List of Figures

Number of Products under Development for Vestibular Diseases, H2 2014 6
Number of Products under Development for Vestibular Diseases - Comparative Analysis, H2 2014 7
Number of Products under Development by Companies, H2 2014 8
Comparative Analysis by Early Stage Products, H2 2014 9
Assessment by Monotherapy Products, H2 2014 14
Number of Products by Top 10 Molecule Types, H2 2014 17
Number of Products by Stage and Top 10 Molecule Types, H2 2014 17

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global and Chinese Otolaryngology Needle Industry, 2016 Market Research Report

Global and Chinese Otolaryngology Needle Industry, 2016 Market Research Report

  • $ 3000
  • Industry report
  • November 2016
  • by Prof Research

The ’Global and Chinese Otolaryngology Needle Industry, 2011-2021 Market Research Report’ is a professional and in-depth study on the current state of the global Otolaryngology Needle industry with ...

Head and neck cancer (HNC) - Epidemiology Forecast To 2023

Head and neck cancer (HNC) - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight “Head and neck cancer (HNC) - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Head and neck cancer (HNC) in seven major markets (US, France, Germany, ...

 Head And Neck Cancer Squamous Cell Carcinoma-Pipeline Insights, 2017

Head And Neck Cancer Squamous Cell Carcinoma-Pipeline Insights, 2017

  • $ 1250
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight’s, “ Head And Neck Cancer Squamous Cell Carcinoma-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Head ...

Head And Neck Cancer

June 2016 $ 5000

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.